Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.

Lumley SF. et al, (2024), J Clin Virol, 174

Corrigendum to A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.: Journal of Clinical Virology 174 (2024) 105711.

Lumley SF. et al, (2024), J Clin Virol, 174

Whole genome sequencing of hepatitis B virus (HBV) using tiled amplicon (HEP-TILE) and probe-based enrichment on Illumina and Nanopore platforms

Lumley SF. et al, (2024)

Peer support for people living with hepatitis B virus-A foundation for treatment expansion.

Downs LO. et al, (2024), J Viral Hepat, 31, 490 - 499

Hepatitis B Core Related Antigen - Does it meet our expectations? Evidence from Cohorts in the United Kingdom and South Africa

Downs LO. et al, (2024)

Multiple risk factors for persistent HBV viraemia in an adult receiving nucleos/tide analogue therapy.

Lumley S. et al, (2024), Sex Transm Infect, 100, 329 - 331

Social, clinical and biological barriers to hepatitis B virus suppression with nucleos/tide analogue therapy: who is at risk and what should we do about it?

Im YR. et al, (2024), Sex Transm Infect, 100, 259 - 263

Addressing pandemic-wide systematic errors in the SARS-CoV-2 phylogeny

Hunt M. et al, (2024)

HEP-TILE: HBV whole genome sequencing (nanopore protocol) v1

Lumley S. et al, (2024)

HEP-TILE: HBV whole genome sequencing (nanopore protocol) v2

Lumley S. et al, (2024)

Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection.

Delphin M. et al, (2024), Lancet Gastroenterol Hepatol, 9, 383 - 392

A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) genotypic resistance in people treated with entecavir or tenofovir

Lumley SF. et al, (2023)

Evaluation of sequence hybridization for respiratory viruses using the Twist Bioscience Respiratory Virus Research panel and the OneCodex Respiratory Virus sequence analysis workflow.

Kapel N. et al, (2023), Microb Genom, 9

Pan-genotypic probe-based enrichment to improve efficiency of Hepatitis B virus sequencing

Lumley SF. et al, (2023)

Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19.

Kotanidis CP. et al, (2022), Lancet Digit Health, 4, e705 - e716

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.

McNaughton AL. et al, (2022), JCI Insight, 7

A new method to identify co-variation in hepatitis B virus whole genome sequences identifies networks of polymorphisms associated with drug resistance

Lumley S. et al, (2022), JOURNAL OF HEPATOLOGY, 77, S856 - S857

SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients.

Shankar S. et al, (2022), J Am Soc Nephrol, 33, 883 - 887

An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status.

Lumley SF. et al, (2022), Clin Infect Dis, 74, 1208 - 1219

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Tomic A. et al, (2022), Nat Commun, 13

Load More